SAB Biotherapeutics, Inc. (SABSW) revenue by segment
SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
$0.01+0.00 (+33.33%)
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
SAB Biotherapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|
| Grant [Member] | $23.90M | $60.88M | $55.24M | 100.0% | -60.7% |
| Grant Revenue [Member] | – | $60.88M | $55.24M | – | – |
By region
From the segment and revenue-disaggregation notes of SAB Biotherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.